-
1
-
-
84982342905
-
Xanthomata, hypercholesterolemia, angina pectoris
-
Müller C. Xanthomata, hypercholesterolemia, angina pectoris. Acta Med. Scand. 2009, 95:75-84. 10.1111/j.0954-6820.1938.tb19279.x.
-
(2009)
Acta Med. Scand.
, vol.95
, pp. 75-84
-
-
Müller, C.1
-
2
-
-
0022549920
-
Areceptor-mediated pathway for cholesterol homeostasis
-
80.
-
Brown M.S., Goldstein J.L. Areceptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:34-47. 80. http://www.ncbi.nlm.nih.gov/pubmed/3513311.
-
(1986)
Science
, vol.232
, pp. 34-47
-
-
Brown, M.S.1
Goldstein, J.L.2
-
3
-
-
84876003260
-
Diagnosis and treatment of familial hypercholesterolaemia
-
Hovingh G.K., Davidson M.H., Kastelein J.J.P., O'Connor A.M. Diagnosis and treatment of familial hypercholesterolaemia. EHJ 2013, 34:962-971.
-
(2013)
EHJ
, vol.34
, pp. 962-971
-
-
Hovingh, G.K.1
Davidson, M.H.2
Kastelein, J.J.P.3
O'Connor, A.M.4
-
4
-
-
84864602990
-
Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29,365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants
-
Huijgen R., Kindt I., Defesche J.C., Kastelein J.J.P. Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29,365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants. Eur. Heart J. 2012, 33:2325-2330. 10.1093/eurheartj/ehs038.
-
(2012)
Eur. Heart J.
, vol.33
, pp. 2325-2330
-
-
Huijgen, R.1
Kindt, I.2
Defesche, J.C.3
Kastelein, J.J.P.4
-
5
-
-
78449281377
-
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials
-
Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. 10.1016/S0140-6736(10)61350-5.
-
(2010)
Lancet
, vol.376
, pp. 1670-1681
-
-
Baigent, C.1
Blackwell, L.2
Emberson, J.3
Holland, L.E.4
Reith, C.5
Bhala, N.6
-
6
-
-
0036607353
-
Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia
-
(accessed 24.10.14).
-
Marks D., Wonderling D., Thorogood M., Lambert H., Humphries S.E., Neil H.A.W. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002, 324:1303. (accessed 24.10.14). http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=113765%26tool=pmcentrez%26rendertype=abstract.
-
(2002)
BMJ
, vol.324
, pp. 1303
-
-
Marks, D.1
Wonderling, D.2
Thorogood, M.3
Lambert, H.4
Humphries, S.E.5
Neil, H.A.W.6
-
7
-
-
0037347780
-
Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening
-
Marks D., Thorogood M., Neil H.a.W., Wonderling D., Humphries S.E. Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening. J.Public Health (Bangkok) 2003, 25:47-52. 10.1093/pubmed/fdg010.
-
(2003)
J.Public Health (Bangkok)
, vol.25
, pp. 47-52
-
-
Marks, D.1
Thorogood, M.2
Neil, H.A.W.3
Wonderling, D.4
Humphries, S.E.5
-
8
-
-
0037603589
-
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
-
Abifadel M., Varret M., Rabès J.-P., Allard D., Ouguerram K., Devillers M., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 2003, 34:154-156. 10.1038/ng1161.
-
(2003)
Nat. Genet.
, vol.34
, pp. 154-156
-
-
Abifadel, M.1
Varret, M.2
Rabès, J.-P.3
Allard, D.4
Ouguerram, K.5
Devillers, M.6
-
9
-
-
0035915685
-
Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands
-
Umans-Eckenhausen M.a, Defesche J.C., Sijbrands E.J., Scheerder R.L., Kastelein J.J. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001, 357:165-168. 10.1016/S0140-6736(00)03587-X.
-
(2001)
Lancet
, vol.357
, pp. 165-168
-
-
Umans-Eckenhausen, M.A.1
Defesche, J.C.2
Sijbrands, E.J.3
Scheerder, R.L.4
Kastelein, J.J.5
-
10
-
-
77049105368
-
Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands
-
Pijlman A., Huijgen R., Verhagen S.N., Imholz B.P.M., Liem a H., Kastelein J.J.P., et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010, 209:189-194. 10.1016/j.atherosclerosis.2009.09.014.
-
(2010)
Atherosclerosis
, vol.209
, pp. 189-194
-
-
Pijlman, A.1
Huijgen, R.2
Verhagen, S.N.3
Imholz, B.P.M.4
Liem, A.H.5
Kastelein, J.J.P.6
-
11
-
-
84934993207
-
Poster abstract - predicting the presence of a mutation resulting in familial hypercholesterolemia - development of a prediction model in a cohort of 64,000 subjects
-
A16172.
-
Besseling J., Reitsma J.B., Hovingh G.K., Hutten B.A. Poster abstract - predicting the presence of a mutation resulting in familial hypercholesterolemia - development of a prediction model in a cohort of 64,000 subjects. Circulation 2014, I30. A16172. http://circ.ahajournals.org/content/130/Suppl_2/A16172.abstract?sid=f32cf69d-7e45-48ac-9083-2df7250c740a.
-
(2014)
Circulation
, vol.I30
-
-
Besseling, J.1
Reitsma, J.B.2
Hovingh, G.K.3
Hutten, B.A.4
-
12
-
-
84924366648
-
Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome
-
[Epub ahead of print]
-
Sjouke B., Kusters D.M., Kindt I., Besseling J., Defesche J.C., Sijbrands E.J.G., et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur. Heart J. 2014, [Epub ahead of print]. 10.1093/eurheartj/ehu058.
-
(2014)
Eur. Heart J.
-
-
Sjouke, B.1
Kusters, D.M.2
Kindt, I.3
Besseling, J.4
Defesche, J.C.5
Sijbrands, E.J.G.6
-
13
-
-
55749088063
-
Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
-
Neil A., Cooper J., Betteridge J., Capps N., McDowell I., Durrington P., et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur. Heart J. 2008, 29:2625-2633. 10.1093/eurheartj/ehn422.
-
(2008)
Eur. Heart J.
, vol.29
, pp. 2625-2633
-
-
Neil, A.1
Cooper, J.2
Betteridge, J.3
Capps, N.4
McDowell, I.5
Durrington, P.6
-
14
-
-
84912082301
-
Reducing the burden of disease and death from familial hypercholesterolemia: a call to action
-
Knowles J.W., O'Brien E.C., Greendale K., Wilemon K., Genest J., Sperling L.S., et al. Reducing the burden of disease and death from familial hypercholesterolemia: a call to action. Am. Heart J. 2014, 168:807-811. 10.1016/j.ahj.2014.09.001.
-
(2014)
Am. Heart J.
, vol.168
, pp. 807-811
-
-
Knowles, J.W.1
O'Brien, E.C.2
Greendale, K.3
Wilemon, K.4
Genest, J.5
Sperling, L.S.6
-
15
-
-
0016373413
-
Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia
-
(accessed 4.12.14)
-
Stone N.J., Levy R.I., Fredrickson D.S., Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974, 49:476-488. (accessed 4.12.14). http://www.ncbi.nlm.nih.gov/pubmed/4813182.
-
(1974)
Circulation
, vol.49
, pp. 476-488
-
-
Stone, N.J.1
Levy, R.I.2
Fredrickson, D.S.3
Verter, J.4
-
16
-
-
0025944056
-
Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific steering committee on behalf of the simon broome register group
-
(accessed 24.10.14)
-
Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific steering committee on behalf of the simon broome register group. BMJ 1991, 303:893-896. (accessed 24.10.14). http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1671226%26tool=pmcentrez%26rendertype=abstract.
-
(1991)
BMJ
, vol.303
, pp. 893-896
-
-
-
17
-
-
84924358878
-
Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus
-
Besseling J., Kastelein J.J.P., Defesche J.C., Hutten B.A., Hovingh G.K. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. J.Am. Med. Assoc. 2015, 313(10):1029-1035. 10.1001/jama.2015.1206.
-
(2015)
J.Am. Med. Assoc.
, vol.313
, Issue.10
, pp. 1029-1035
-
-
Besseling, J.1
Kastelein, J.J.P.2
Defesche, J.C.3
Hutten, B.A.4
Hovingh, G.K.5
-
18
-
-
77950174523
-
Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal
-
Huijgen R., Kindt I., Verhoeven S.B.J., Sijbrands E.J.G., Vissers M.N., Kastelein J.J.P., et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One 2010, 5:e9220. 10.1371/journal.pone.0009220.
-
(2010)
PLoS One
, vol.5
, pp. e9220
-
-
Huijgen, R.1
Kindt, I.2
Verhoeven, S.B.J.3
Sijbrands, E.J.G.4
Vissers, M.N.5
Kastelein, J.J.P.6
-
19
-
-
84901591020
-
Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study
-
Sjouke B., Langslet G., Ceska R., Nicholls S.J., Nissen S.E., Öhlander M., et al. Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Diabetes Endocrinol. 2014, 2:455-463. 10.1016/S2213-8587(14)70006-3.
-
(2014)
Lancet Diabetes Endocrinol.
, vol.2
, pp. 455-463
-
-
Sjouke, B.1
Langslet, G.2
Ceska, R.3
Nicholls, S.J.4
Nissen, S.E.5
Öhlander, M.6
-
20
-
-
84930088585
-
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study
-
Kastelein J.J.P., Besseling J., Shah S., Bergeron J., Langslet G., Hovingh G.K., et al. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet 2015, 6736:1-9. 10.1016/S0140-6736(14)62115-2.
-
(2015)
Lancet
, vol.6736
, pp. 1-9
-
-
Kastelein, J.J.P.1
Besseling, J.2
Shah, S.3
Bergeron, J.4
Langslet, G.5
Hovingh, G.K.6
-
21
-
-
79960205374
-
ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS)
-
Catapano A.L., Reiner Z., De Backer G., Graham I., Taskinen M.-R., Wiklund O., et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS). Atherosclerosis 2011, 217(Suppl.l):S1-S44. 10.1016/j.atherosclerosis.2011.06.012.
-
(2011)
Atherosclerosis
, vol.217
, Issue.SUPPL.l
, pp. S1-S44
-
-
Catapano, A.L.1
Reiner, Z.2
De Backer, G.3
Graham, I.4
Taskinen, M.-R.5
Wiklund, O.6
-
22
-
-
84890461947
-
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis Society
-
[Epub ahead of print]
-
Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis Society. Eur. Heart J. 2013, [Epub ahead of print]. 10.1093/eurheartj/eht273.
-
(2013)
Eur. Heart J.
-
-
Nordestgaard, B.G.1
Chapman, M.J.2
Humphries, S.E.3
Ginsberg, H.N.4
Masana, L.5
Descamps, O.S.6
-
23
-
-
0035941786
-
Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial
-
Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J., Stalenhoef A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001, 357:577-581.
-
(2001)
Lancet
, vol.357
, pp. 577-581
-
-
Smilde, T.J.1
van Wissen, S.2
Wollersheim, H.3
Trip, M.D.4
Kastelein, J.J.5
Stalenhoef, A.F.6
-
24
-
-
0346962889
-
Treating to new targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?
-
Waters D.D., Guyton J.R., Herrington D.M., McGowan M.P., Wenger N.K., Shear C. Treating to new targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. Am. J. Cardiol. 2004, 93:154-158.
-
(2004)
Am. J. Cardiol.
, vol.93
, pp. 154-158
-
-
Waters, D.D.1
Guyton, J.R.2
Herrington, D.M.3
McGowan, M.P.4
Wenger, N.K.5
Shear, C.6
-
25
-
-
84934932312
-
Trial summary improve-it
-
Kuhmbani D.J. Trial summary improve-it. Trial Summ. 2014, http://www.cardiosource.org/Science-And-Quality/Clinical-Trials/I/IMPROVE-IT.aspx.
-
(2014)
Trial Summ.
-
-
Kuhmbani, D.J.1
-
26
-
-
84902576469
-
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines
-
Stone N.J., Robinson J.G., Lichtenstein A.H., Bairey Merz C.N., Blum C.B., Eckel R.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. JACC 2013, 63:2889-2934. 10.1016/j.jacc.2013.11.002.
-
(2013)
JACC
, vol.63
, pp. 2889-2934
-
-
Stone, N.J.1
Robinson, J.G.2
Lichtenstein, A.H.3
Bairey Merz, C.N.4
Blum, C.B.5
Eckel, R.H.6
-
27
-
-
84931028781
-
Mortality among patients with familial hypercholesterolemia: a registry-based study in norway, 1992-2010
-
Mundal L., Sarancic M., Ose L., Iversen P.O., Borgan J.-K., Veierød M.B., et al. Mortality among patients with familial hypercholesterolemia: a registry-based study in norway, 1992-2010. J.Am. Heart Assoc. 2014, 3:1-9. 10.1161/JAHA.114.001236.
-
(2014)
J.Am. Heart Assoc.
, vol.3
, pp. 1-9
-
-
Mundal, L.1
Sarancic, M.2
Ose, L.3
Iversen, P.O.4
Borgan, J.-K.5
Veierød, M.B.6
-
28
-
-
0032500649
-
Identification of a form of acyl-CoA:cholesterol acyltransferase specific to liver and intestine in nonhuman primates
-
Anderson R.A., Joyce C., Davis M., Reagan J.W., Clark M., Shelness G.S., et al. Identification of a form of acyl-CoA:cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J.Biol. Chem. 1998, 273:26747-26754. 10.1074/jbc.273.41.26747.
-
(1998)
J.Biol. Chem.
, vol.273
, pp. 26747-26754
-
-
Anderson, R.A.1
Joyce, C.2
Davis, M.3
Reagan, J.W.4
Clark, M.5
Shelness, G.S.6
-
29
-
-
33746082034
-
And then there were acyl coenzyme A:cholesterol acyl transferase inhibitors
-
Meuwese M.C., Franssen R., Stroes E.S.G., Kastelein J.J.P. And then there were acyl coenzyme A:cholesterol acyl transferase inhibitors. Curr. Opin. Lipidol. 2006, 17:426-430. 10.1097/01.mol.0000236369.50378.6e.
-
(2006)
Curr. Opin. Lipidol.
, vol.17
, pp. 426-430
-
-
Meuwese, M.C.1
Franssen, R.2
Stroes, E.S.G.3
Kastelein, J.J.P.4
-
30
-
-
0034529633
-
Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice
-
Buhman K.K., Accad M., Novak S., Choi R.S., Wong J.S., Hamilton R.L., et al. Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice. Nat. Med. 2000, 6:1341-1347. 10.1038/82153.
-
(2000)
Nat. Med.
, vol.6
, pp. 1341-1347
-
-
Buhman, K.K.1
Accad, M.2
Novak, S.3
Choi, R.S.4
Wong, J.S.5
Hamilton, R.L.6
-
31
-
-
7044235261
-
ACAT2 deficiency limits cholesterol absorption in the cholesterol-fed mouse: Impact on hepatic cholesterol homeostasis
-
Repa J.J., Buhman K.K., Farese R.V., Dietschy J.M., Turley S.D. ACAT2 deficiency limits cholesterol absorption in the cholesterol-fed mouse: Impact on hepatic cholesterol homeostasis. Hepatology 2004, 40:1088-1097. 10.1002/hep.20439.
-
(2004)
Hepatology
, vol.40
, pp. 1088-1097
-
-
Repa, J.J.1
Buhman, K.K.2
Farese, R.V.3
Dietschy, J.M.4
Turley, S.D.5
-
32
-
-
0034965751
-
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia
-
Insull W., Koren M., Davignon J., Sprecher D., Schrott H., Keilson L.M., et al. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis 2001, 157:137-144. 10.1016/S0021-9150(00)00615-8.
-
(2001)
Atherosclerosis
, vol.157
, pp. 137-144
-
-
Insull, W.1
Koren, M.2
Davignon, J.3
Sprecher, D.4
Schrott, H.5
Keilson, L.M.6
-
33
-
-
0344896639
-
Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia
-
Raal F.J., Marais A.D., Klepack E., Lovalvo J., McLain R., Heinonen T. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis 2003, 171:273-279. 10.1016/j.atherosclerosis.2003.07.011.
-
(2003)
Atherosclerosis
, vol.171
, pp. 273-279
-
-
Raal, F.J.1
Marais, A.D.2
Klepack, E.3
Lovalvo, J.4
McLain, R.5
Heinonen, T.6
-
34
-
-
20844449696
-
Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions
-
Tardif J.C., Grégoire J., L'Allier P.L., Anderson T.J., Bertrand O., Reeves F., et al. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 2004, 110:3372-3377. 10.1161/01.CIR.0000147777.12010.EF.
-
(2004)
Circulation
, vol.110
, pp. 3372-3377
-
-
Tardif, J.C.1
Grégoire, J.2
L'Allier, P.L.3
Anderson, T.J.4
Bertrand, O.5
Reeves, F.6
-
35
-
-
33645097996
-
-
Nissen S.E., Tuzcu E.M., Brewer H.B., Sipahi I., Nicholls S.J., Ganz P., et al. Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis 2006, 10.1056/NEJMoa054699.
-
(2006)
Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis
-
-
Nissen, S.E.1
Tuzcu, E.M.2
Brewer, H.B.3
Sipahi, I.4
Nicholls, S.J.5
Ganz, P.6
-
36
-
-
62649118779
-
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial
-
Meuwese M.C., de Groot E., Duivenvoorden R., Trip M.D., Ose L., Maritz F.J., et al. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. J.Am. Med. Assoc. 2009, 301:1131-1139. 10.1001/jama.301.11.1131.
-
(2009)
J.Am. Med. Assoc.
, vol.301
, pp. 1131-1139
-
-
Meuwese, M.C.1
de Groot, E.2
Duivenvoorden, R.3
Trip, M.D.4
Ose, L.5
Maritz, F.J.6
-
37
-
-
0033827087
-
APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation
-
Davidson N.O., Shelness G.S. APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu Rev. Nutr. 2000, 20:169-193. 10.1146/annurev.nutr.20.1.169.
-
(2000)
Annu Rev. Nutr.
, vol.20
, pp. 169-193
-
-
Davidson, N.O.1
Shelness, G.S.2
-
38
-
-
79955026955
-
Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice
-
Mullick A.E., Fu W., Graham M.J., Lee R.G., Witchell D., Bell T.a, et al. Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice. J.Lipid Res. 2011, 52:885-896. 10.1194/jlr.M011791.
-
(2011)
J.Lipid Res.
, vol.52
, pp. 885-896
-
-
Mullick, A.E.1
Fu, W.2
Graham, M.J.3
Lee, R.G.4
Witchell, D.5
Bell, T.A.6
-
39
-
-
84868518061
-
Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease
-
Stein E.a, Dufour R., Gagne C., Gaudet D., East C., Donovan J.M., et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012, 126:2283-2292. 10.1161/CIRCULATIONAHA.112.104125.
-
(2012)
Circulation
, vol.126
, pp. 2283-2292
-
-
Stein, E.A.1
Dufour, R.2
Gagne, C.3
Gaudet, D.4
East, C.5
Donovan, J.M.6
-
40
-
-
77949485460
-
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
-
Raal F.J., Santos R.D., Blom D.J., Marais a D., Charng M.-J., Cromwell W.C., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:998-1006. 10.1016/S0140-6736(10)60284-X.
-
(2010)
Lancet
, vol.375
, pp. 998-1006
-
-
Raal, F.J.1
Santos, R.D.2
Blom, D.J.3
Marais, A.D.4
Charng, M.-J.5
Cromwell, W.C.6
-
41
-
-
84924415690
-
Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
-
[Epub ahead of print]
-
Santos R.D., Duell P.B., East C., Guyton J.R., Moriarty P.M., Chin W., et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur. Heart J. 2013, [Epub ahead of print]. 10.1093/eurheartj/eht549.
-
(2013)
Eur. Heart J.
-
-
Santos, R.D.1
Duell, P.B.2
East, C.3
Guyton, J.R.4
Moriarty, P.M.5
Chin, W.6
-
42
-
-
84888090979
-
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial
-
Thomas G.S., Cromwell W.C., Ali S., Chin W., Flaim J.D., Davidson M. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. JACC 2013, 62:2178-2184. 10.1016/j.jacc.2013.07.081.
-
(2013)
JACC
, vol.62
, pp. 2178-2184
-
-
Thomas, G.S.1
Cromwell, W.C.2
Ali, S.3
Chin, W.4
Flaim, J.D.5
Davidson, M.6
-
43
-
-
84869039132
-
Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy
-
McGowan M.P., Tardif J.-C., Ceska R., Burgess L.J., Soran H., Gouni-Berthold I., et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One 2012, 7:e49006. 10.1371/journal.pone.0049006.
-
(2012)
PLoS One
, vol.7
, pp. e49006
-
-
McGowan, M.P.1
Tardif, J.-C.2
Ceska, R.3
Burgess, L.J.4
Soran, H.5
Gouni-Berthold, I.6
-
44
-
-
84928828932
-
Liver histology during mipomersen therapy for severe hypercholesterolemia
-
Hashemi N., Odze R.D., McGowan M.P., Santos R.D., Stroes E.S.G., Cohen D.E. Liver histology during mipomersen therapy for severe hypercholesterolemia. J.Clin. Lipidol. 2014, 8:606-611. 10.1016/j.jacl.2014.08.002.
-
(2014)
J.Clin. Lipidol.
, vol.8
, pp. 606-611
-
-
Hashemi, N.1
Odze, R.D.2
McGowan, M.P.3
Santos, R.D.4
Stroes, E.S.G.5
Cohen, D.E.6
-
45
-
-
84904663172
-
Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers
-
Flaim J.D., Grundy J.S., Baker B.F., McGowan M.P., Kastelein J.J.P. Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers. J.Am. Heart Assoc. 2014, 3:e000560. 10.1161/JAHA.113.000560.
-
(2014)
J.Am. Heart Assoc.
, vol.3
, pp. e000560
-
-
Flaim, J.D.1
Grundy, J.S.2
Baker, B.F.3
McGowan, M.P.4
Kastelein, J.J.P.5
-
46
-
-
84884487596
-
Journey through cholesteryl ester transfer protein inhibition: from bench to bedside
-
Karalis I., Rensen P.C.N., Jukema J.W. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside. Circ. Cardiovasc. Qual. Outcomes 2013, 6:360-366. 10.1161/CIRCOUTCOMES.111.000014.
-
(2013)
Circ. Cardiovasc. Qual. Outcomes
, vol.6
, pp. 360-366
-
-
Karalis, I.1
Rensen, P.C.N.2
Jukema, J.W.3
-
47
-
-
0034644214
-
Acholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
-
Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., Shinkai H. Acholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000, 406:203-207. 10.1038/35018119.
-
(2000)
Nature
, vol.406
, pp. 203-207
-
-
Okamoto, H.1
Yonemori, F.2
Wakitani, K.3
Minowa, T.4
Maeda, K.5
Shinkai, H.6
-
48
-
-
0034925152
-
Cholesteryl ester transfer protein, high density lipoprotein and arterial disease
-
Barter P.J., Rye K.a Cholesteryl ester transfer protein, high density lipoprotein and arterial disease. Curr. Opin. Lipidol. 2001, 12:377-382. http://www.ncbi.nlm.nih.gov/pubmed/11507321.
-
(2001)
Curr. Opin. Lipidol.
, vol.12
, pp. 377-382
-
-
Barter, P.J.1
Rye, K.A.2
-
49
-
-
78549235583
-
Safety of anacetrapib in patients with or at high risk for coronary heart disease
-
Cannon C.P., Shah S., Dansky H.M., Davidson M., Brinton E.a, Gotto A.M., et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. NEJM 2010, 363:2406-2415. 10.1056/NEJMoa1009744.
-
(2010)
NEJM
, vol.363
, pp. 2406-2415
-
-
Cannon, C.P.1
Shah, S.2
Dansky, H.M.3
Davidson, M.4
Brinton, E.A.5
Gotto, A.M.6
-
50
-
-
81255125373
-
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial
-
Nicholls S.J., Brewer H.B., Kastelein J.J.P., Krueger K.A., Hu B., McErlean E., et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. J.Am. Med. Assoc. 2011, 306:2099-2109. 10.1001/jama.2011.1649.
-
(2011)
J.Am. Med. Assoc.
, vol.306
, pp. 2099-2109
-
-
Nicholls, S.J.1
Brewer, H.B.2
Kastelein, J.J.P.3
Krueger, K.A.4
Hu, B.5
McErlean, E.6
-
51
-
-
84904252744
-
Effects of extended-release niacin with Laropiprant in high-risk patients
-
Parish S., Tomson J., Wallendszus K., Craig M., Service C.T., Jiang L., et al. Effects of extended-release niacin with Laropiprant in high-risk patients. NEJM 2014, 371:203-212. 10.1056/NEJMoa1300955.
-
(2014)
NEJM
, vol.371
, pp. 203-212
-
-
Parish, S.1
Tomson, J.2
Wallendszus, K.3
Craig, M.4
Service, C.T.5
Jiang, L.6
-
52
-
-
84855171302
-
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
-
Boden W.E., Probstfield J.L., Anderson T., Chaitman B.R., Desvignes-Nickens P., Koprowicz K., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. NEJM 2011, 365:2255-2267.
-
(2011)
NEJM
, vol.365
, pp. 2255-2267
-
-
Boden, W.E.1
Probstfield, J.L.2
Anderson, T.3
Chaitman, B.R.4
Desvignes-Nickens, P.5
Koprowicz, K.6
-
53
-
-
34247241088
-
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia
-
Kastelein J.J.P., van Leuven S.I., Burgess L., Evans G.W., Kuivenhoven J.A., Barter P.J., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. NEJM 2007, 356:1620-1630. 10.1056/NEJMoa071359.
-
(2007)
NEJM
, vol.356
, pp. 1620-1630
-
-
Kastelein, J.J.P.1
van Leuven, S.I.2
Burgess, L.3
Evans, G.W.4
Kuivenhoven, J.A.5
Barter, P.J.6
-
54
-
-
84870045994
-
Effects of dalcetrapib in patients with a recent acute coronary syndrome
-
Schwartz G.G., Olsson A.G., Abt M., Ballantyne C.M., Barter P.J., Brumm J., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. NEJM 2012, 367:2089-2099. 10.1056/NEJMoa1206797.
-
(2012)
NEJM
, vol.367
, pp. 2089-2099
-
-
Schwartz, G.G.1
Olsson, A.G.2
Abt, M.3
Ballantyne, C.M.4
Barter, P.J.5
Brumm, J.6
-
55
-
-
84934924121
-
Poster abstract - randomized evaluation of anacetrapib lipid-modifying therapy in patients with HeteroZygous familial HypercholesterolEmia (REALIZE study)
-
(REALIZE S.-P.
-
Kastelein J.J., Besseling J., Shah S., Bergeron J., Langslet G., Hovingh G.K., et al. Poster abstract - randomized evaluation of anacetrapib lipid-modifying therapy in patients with HeteroZygous familial HypercholesterolEmia (REALIZE study). Circulation 2014, I30. (REALIZE S.-P. abstract, A9613. http://circ.ahajournals.org/content/130/Suppl_2/A9613.abstract?sid=4a3cc7ae-cd77-4efa-b3cb-8b9d9845cdae.
-
(2014)
Circulation
, vol.I30
-
-
Kastelein, J.J.1
Besseling, J.2
Shah, S.3
Bergeron, J.4
Langslet, G.5
Hovingh, G.K.6
-
56
-
-
84938748425
-
Cholesterol ester transfer protein (CETP) inhibition by TA-8995 inpatients with mild dyslipidemia (TULIP); a randomised, double-blind, placebo-controlled trial
-
[Epub ahead of print]
-
Hovingh G.K., Kastelein J.J., van Deventer S.J., Round P., Ford J., Saleheen D., et al. Cholesterol ester transfer protein (CETP) inhibition by TA-8995 inpatients with mild dyslipidemia (TULIP); a randomised, double-blind, placebo-controlled trial. Lancet 2015, [Epub ahead of print].
-
(2015)
Lancet
-
-
Hovingh, G.K.1
Kastelein, J.J.2
van Deventer, S.J.3
Round, P.4
Ford, J.5
Saleheen, D.6
-
57
-
-
84919343998
-
HDL cholesterol efflux capacity and incident cardiovascular events
-
Rohatgi A., Khera A., Berry J.D., Givens E.G., Ayers C.R., Wedin K.E., et al. HDL cholesterol efflux capacity and incident cardiovascular events. NEJM 2014, 317:2383-2393. 10.1056/NEJMoa1409065.
-
(2014)
NEJM
, vol.317
, pp. 2383-2393
-
-
Rohatgi, A.1
Khera, A.2
Berry, J.D.3
Givens, E.G.4
Ayers, C.R.5
Wedin, K.E.6
-
58
-
-
0027428820
-
Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia
-
Sharp D., Blinderman L., Combs K.A., Kienzle B., Ricci B., Wager-Smith K., et al. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 1993, 365:65-69. 10.1038/365065a0.
-
(1993)
Nature
, vol.365
, pp. 65-69
-
-
Sharp, D.1
Blinderman, L.2
Combs, K.A.3
Kienzle, B.4
Ricci, B.5
Wager-Smith, K.6
-
59
-
-
0032561425
-
An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits
-
Wetterau J.R., Gregg R.E., Harrity T.W., Arbeeny C., Cap M., Connolly F., et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998, 282:751-754. 10.1126/science.282.5389.751.
-
(1998)
Science
, vol.282
, pp. 751-754
-
-
Wetterau, J.R.1
Gregg, R.E.2
Harrity, T.W.3
Arbeeny, C.4
Cap, M.5
Connolly, F.6
-
60
-
-
33846151732
-
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
-
Cuchel M., Bloedon L.T., Szapary P.O., Kolansky D.M., Wolfe M.L., Sarkis A., et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. NEJM 2007, 356:148-156. 10.1056/NEJMoa061189.
-
(2007)
NEJM
, vol.356
, pp. 148-156
-
-
Cuchel, M.1
Bloedon, L.T.2
Szapary, P.O.3
Kolansky, D.M.4
Wolfe, M.L.5
Sarkis, A.6
-
61
-
-
84871945617
-
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
-
Cuchel M., Meagher E.a, Toit Theron H.du, Blom D.J., Marais A.D., Hegele R.A., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013, 381:40-46. 10.1016/S0140-6736(12)61731-0.
-
(2013)
Lancet
, vol.381
, pp. 40-46
-
-
Cuchel, M.1
Meagher, E.A.2
Toit Theron, H.D.3
Blom, D.J.4
Marais, A.D.5
Hegele, R.A.6
-
62
-
-
84908131271
-
Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia
-
Cuchel M., Blom D.J., Averna M.R. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. Atheroscler 2014, (Suppl.15):33-45. 10.1016/j.atherosclerosissup.2014.07.005.
-
(2014)
Atheroscler
, Issue.SUPPL.15
, pp. 33-45
-
-
Cuchel, M.1
Blom, D.J.2
Averna, M.R.3
-
63
-
-
79960539641
-
ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
-
Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.-R., Wiklund O., et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011, 32:1769-1818. 10.1093/eurheartj/ehr158.
-
(2011)
Eur. Heart J.
, vol.32
, pp. 1769-1818
-
-
Reiner, Z.1
Catapano, A.L.2
De Backer, G.3
Graham, I.4
Taskinen, M.-R.5
Wiklund, O.6
-
64
-
-
84897584807
-
Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide
-
Sacks F.M., Stanesa M., Hegele R.a Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide. J.Am. Med. Assoc. Intern. Med. 2014, 174:443-447. 10.1001/jamainternmed.2013.13309.
-
(2014)
J.Am. Med. Assoc. Intern. Med.
, vol.174
, pp. 443-447
-
-
Sacks, F.M.1
Stanesa, M.2
Hegele, R.A.3
-
65
-
-
84869025466
-
The PCSK9 decade
-
Lambert G., Sjouke B., Choque B., Kastelein J.J.P., Hovingh G.K. The PCSK9 decade. J.Lipid Res. 2012, 53:2515-2524. 10.1194/jlr.R026658.
-
(2012)
J.Lipid Res.
, vol.53
, pp. 2515-2524
-
-
Lambert, G.1
Sjouke, B.2
Choque, B.3
Kastelein, J.J.P.4
Hovingh, G.K.5
-
66
-
-
84904525083
-
Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs
-
Abifadel M., Elbitar S., El Khoury P., Ghaleb Y., Chémaly M., Moussalli M.L., et al. Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. Curr. Atheroscler. Rep. 2014, 16. 10.1007/s11883-014-0439-8.
-
(2014)
Curr. Atheroscler. Rep.
, vol.16
-
-
Abifadel, M.1
Elbitar, S.2
El Khoury, P.3
Ghaleb, Y.4
Chémaly, M.5
Moussalli, M.L.6
-
67
-
-
84868206496
-
Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins
-
Dias C.S., Shaywitz A.J., Wasserman S.M., Smith B.P., Gao B., Stolman D.S., et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J.Am. Coll. Cardiol. 2012, 60:1888-1898. 10.1016/j.jacc.2012.08.986.
-
(2012)
J.Am. Coll. Cardiol.
, vol.60
, pp. 1888-1898
-
-
Dias, C.S.1
Shaywitz, A.J.2
Wasserman, S.M.3
Smith, B.P.4
Gao, B.5
Stolman, D.S.6
-
68
-
-
84869220345
-
Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 Inhibiti
-
Raal F., Scott R., Somaratne R., Bridges I., Li G., Wasserman S.M., et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 Inhibiti. Circulation 2012, 126:2408-2417. 10.1161/CIRCULATIONAHA.112.144055.
-
(2012)
Circulation
, vol.126
, pp. 2408-2417
-
-
Raal, F.1
Scott, R.2
Somaratne, R.3
Bridges, I.4
Li, G.5
Wasserman, S.M.6
-
69
-
-
84899846576
-
A52-week placebo-controlled trial of evolocumab in hyperlipidemia
-
Blom D.J., Hala T., Bolognese M., Lillestol M.J., Toth P.D., Burgess L., et al. A52-week placebo-controlled trial of evolocumab in hyperlipidemia. N.Engl. J. Med. 2014, 370:1809-1819. 10.1056/NEJMoa1316222.
-
(2014)
N.Engl. J. Med.
, vol.370
, pp. 1809-1819
-
-
Blom, D.J.1
Hala, T.2
Bolognese, M.3
Lillestol, M.J.4
Toth, P.D.5
Burgess, L.6
-
70
-
-
84871326497
-
Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial
-
Sullivan D., Olsson A.G., Scott R., Kim J.B., Xue A., Gebski V., et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. J.Am. Med. Assoc. 2012, 308:2497-2506. 10.1001/jama.2012.25790.
-
(2012)
J.Am. Med. Assoc.
, vol.308
, pp. 2497-2506
-
-
Sullivan, D.1
Olsson, A.G.2
Scott, R.3
Kim, J.B.4
Xue, A.5
Gebski, V.6
-
71
-
-
84870478439
-
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 stu
-
Giugliano R.P., Desai N.R., Kohli P., Rogers W.J., Somaratne R., Huang F., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 stu. Lancet 2012, 380:2007-2017. 10.1016/S0140-6736(12)61770-X.
-
(2012)
Lancet
, vol.380
, pp. 2007-2017
-
-
Giugliano, R.P.1
Desai, N.R.2
Kohli, P.3
Rogers, W.J.4
Somaratne, R.5
Huang, F.6
-
72
-
-
84902142901
-
Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab
-
Koren M.J., Lundqvist P., Bolognese M., Neutel J.M., Monsalvo M.L., Yang J., et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J.Am. Coll. Cardiol. 2014, 63:2531-2540. 10.1016/j.jacc.2014.03.018.
-
(2014)
J.Am. Coll. Cardiol.
, vol.63
, pp. 2531-2540
-
-
Koren, M.J.1
Lundqvist, P.2
Bolognese, M.3
Neutel, J.M.4
Monsalvo, M.L.5
Yang, J.6
-
73
-
-
84900303213
-
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial
-
Robinson J.G., Nedergaard B.S., Rogers W.J., Fialkow J., Neutel J.M., Ramstad D., et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. J.Am. Med. Assoc. 2014, 311:1870-1882. 10.1001/jama.2014.4030.
-
(2014)
J.Am. Med. Assoc.
, vol.311
, pp. 1870-1882
-
-
Robinson, J.G.1
Nedergaard, B.S.2
Rogers, W.J.3
Fialkow, J.4
Neutel, J.M.5
Ramstad, D.6
-
74
-
-
84921483643
-
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
-
Raal F.J., Stein E.a, Dufour R., Turner T., Civeira F., Burgess L., et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2014, 6736:1-10. 10.1016/S0140-6736(14)61399-4.
-
(2014)
Lancet
, vol.6736
, pp. 1-10
-
-
Raal, F.J.1
Stein, E.A.2
Dufour, R.3
Turner, T.4
Civeira, F.5
Burgess, L.6
-
75
-
-
84887164358
-
Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia
-
Stein E.A., Honarpour N., Wasserman S.M., Xu F., Scott R., Raal F.J. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013, 128:2113-2120. 10.1161/CIRCULATIONAHA.113.004678.
-
(2013)
Circulation
, vol.128
, pp. 2113-2120
-
-
Stein, E.A.1
Honarpour, N.2
Wasserman, S.M.3
Xu, F.4
Scott, R.5
Raal, F.J.6
-
76
-
-
84921459685
-
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
-
Raal F.J., Honarpour N., Blom D.J., Hovingh G.K., Xu F., Scott R., et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2014, 6736:1-10. 10.1016/S0140-6736(14)61374-X.
-
(2014)
Lancet
, vol.6736
, pp. 1-10
-
-
Raal, F.J.1
Honarpour, N.2
Blom, D.J.3
Hovingh, G.K.4
Xu, F.5
Scott, R.6
-
77
-
-
84902157271
-
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab
-
Stroes E., Colquhoun D., Sullivan D., Civeira F., Rosenson R.S., Watts G.F., et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J.Am. Coll. Cardiol. 2014, 63:2541-2548. 10.1016/j.jacc.2014.03.019.
-
(2014)
J.Am. Coll. Cardiol.
, vol.63
, pp. 2541-2548
-
-
Stroes, E.1
Colquhoun, D.2
Sullivan, D.3
Civeira, F.4
Rosenson, R.S.5
Watts, G.F.6
-
78
-
-
84892679366
-
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial
-
Koren M.J., Giugliano R.P., Raal F.J., Sullivan D., Bolognese M., Langslet G., et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial. Circulation 2014, 129:234-243. 10.1161/CIRCULATIONAHA.113.007012.
-
(2014)
Circulation
, vol.129
, pp. 234-243
-
-
Koren, M.J.1
Giugliano, R.P.2
Raal, F.J.3
Sullivan, D.4
Bolognese, M.5
Langslet, G.6
-
79
-
-
84922670093
-
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials
-
Stein E.A., Giugliano R.P., Koren M.J., Raal F.J., Roth E.M., Weiss R., et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur. Heart J. 2014, 10.1093/eurheartj/ehu085.
-
(2014)
Eur. Heart J.
-
-
Stein, E.A.1
Giugliano, R.P.2
Koren, M.J.3
Raal, F.J.4
Roth, E.M.5
Weiss, R.6
-
80
-
-
84858638369
-
Effect of a monoclonal antibody to PCSK9 on LDL cholesterol
-
Stein E.A., Mellis S., Yancopoulos G.D., Stahl N., Logan D., Smith W.B., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. NEJM 2012, 366:1108-1118. 10.1056/NEJMoa1105803.
-
(2012)
NEJM
, vol.366
, pp. 1108-1118
-
-
Stein, E.A.1
Mellis, S.2
Yancopoulos, G.D.3
Stahl, N.4
Logan, D.5
Smith, W.B.6
-
81
-
-
84868689211
-
Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia
-
Roth E.M., McKenney J.M., Hanotin C., Asset G., Stein E.a Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N.Engl. J. Med. 2012, 367:1891-1900. 10.1056/NEJMoa1201832.
-
(2012)
N.Engl. J. Med.
, vol.367
, pp. 1891-1900
-
-
Roth, E.M.1
McKenney, J.M.2
Hanotin, C.3
Asset, G.4
Stein, E.A.5
-
82
-
-
84862219022
-
Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy
-
McKenney J.M., Koren M.J., Kereiakes D.J., Hanotin C., Ferrand A.-C., Stein E.A. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J.Am. Coll. Cardiol. 2012, 59:2344-2353. 10.1016/j.jacc.2012.03.007.
-
(2012)
J.Am. Coll. Cardiol.
, vol.59
, pp. 2344-2353
-
-
McKenney, J.M.1
Koren, M.J.2
Kereiakes, D.J.3
Hanotin, C.4
Ferrand, A.-C.5
Stein, E.A.6
-
83
-
-
84904383126
-
Efficacy and saftey of bococizumab (RN316/PF-04950615), a monocolonal antibody against proprotein convertase subtilsin/kexin type 9 in statin-treated hypercholesterolemic subjects: results from a randomized, placebo-controlled, dose-ranging study
-
A1374.
-
Ballantyne C.M., Neutel J., Cropp A., Duggan W., Wang E., Plowchalk D., et al. Efficacy and saftey of bococizumab (RN316/PF-04950615), a monocolonal antibody against proprotein convertase subtilsin/kexin type 9 in statin-treated hypercholesterolemic subjects: results from a randomized, placebo-controlled, dose-ranging study. J.Am. Coll. Cardiol. 2014, 63. A1374. 10.1016/S0735-1097(14)61374-7.
-
(2014)
J.Am. Coll. Cardiol.
, vol.63
-
-
Ballantyne, C.M.1
Neutel, J.2
Cropp, A.3
Duggan, W.4
Wang, E.5
Plowchalk, D.6
-
84
-
-
67649961784
-
Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia
-
Seiki S., Frishman W.H. Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia. Cardiol. Rev. 2009, 17:70-76. 10.1097/CRD.0b013e3181885905.
-
(2009)
Cardiol. Rev.
, vol.17
, pp. 70-76
-
-
Seiki, S.1
Frishman, W.H.2
-
85
-
-
58149202133
-
Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway
-
Do R., Kiss R.S., Gaudet D., Engert J.C. Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway. Clin. Genet. 2009, 75:19-29. 10.1111/j.1399-0004.2008.01099.x.
-
(2009)
Clin. Genet.
, vol.75
, pp. 19-29
-
-
Do, R.1
Kiss, R.S.2
Gaudet, D.3
Engert, J.C.4
-
86
-
-
79955762929
-
Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia
-
Stein E.A., Bays H., O'Brien D., Pedicano J., Piper E., Spezzi A. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation 2011, 123:1974-1985. 10.1161/CIRCULATIONAHA.110.975284.
-
(2011)
Circulation
, vol.123
, pp. 1974-1985
-
-
Stein, E.A.1
Bays, H.2
O'Brien, D.3
Pedicano, J.4
Piper, E.5
Spezzi, A.6
-
87
-
-
9744282076
-
Effect of thyroid extract on serum lipoproteins and serum cholesterol
-
Strisower B., Gofman J.W., Galioni E.F., Almada A.A., Simon A. Effect of thyroid extract on serum lipoproteins and serum cholesterol. Metabolism 1954, 3:218-227.
-
(1954)
Metabolism
, vol.3
, pp. 218-227
-
-
Strisower, B.1
Gofman, J.W.2
Galioni, E.F.3
Almada, A.A.4
Simon, A.5
-
88
-
-
9744252485
-
Effect of long-term administration of desiccated thyroid on serum lipoprotein and cholesterol levels
-
Strisower B., Gofman J.W., Galioni E.F., Rubinger J.H., O'Brien G.W., Simon A. Effect of long-term administration of desiccated thyroid on serum lipoprotein and cholesterol levels. J.Clin. Endocrinol. Metab. 1955, 15:73-80.
-
(1955)
J.Clin. Endocrinol. Metab.
, vol.15
, pp. 73-80
-
-
Strisower, B.1
Gofman, J.W.2
Galioni, E.F.3
Rubinger, J.H.4
O'Brien, G.W.5
Simon, A.6
-
90
-
-
77749270649
-
Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study
-
Ladenson P.W., McCarren M., Morkin E., Edson R.G., Shih M.C., Warren S.R., et al. Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study. J.Clin. Endocrinol. Metab. 2010, 95:1349-1354. 10.1210/jc.2009-1209.
-
(2010)
J.Clin. Endocrinol. Metab.
, vol.95
, pp. 1349-1354
-
-
Ladenson, P.W.1
McCarren, M.2
Morkin, E.3
Edson, R.G.4
Shih, M.C.5
Warren, S.R.6
-
91
-
-
84870167700
-
Thyroid hormone receptor agonists reduce serum cholesterol independent of the LDL receptor
-
Lin J.Z., Martagón A.J., Hsueh W.A., Baxter J.D., Gustafsson J.Å., Webb P., et al. Thyroid hormone receptor agonists reduce serum cholesterol independent of the LDL receptor. Endocrinology 2012, 153:6136-6144. 10.1210/en.2011-2081.
-
(2012)
Endocrinology
, vol.153
, pp. 6136-6144
-
-
Lin, J.Z.1
Martagón, A.J.2
Hsueh, W.A.3
Baxter, J.D.4
Gustafsson, J.Å.5
Webb, P.6
-
92
-
-
65449171996
-
Thyroid hormone β receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys
-
Ito B.R., Zhang B.H., Cable E.E., Song X., Fujitaki J.M., MacKenna D.A., et al. Thyroid hormone β receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Br. J. Pharmacol. 2009, 156:454-465. 10.1111/j.1750-3639.2009.00038.x.
-
(2009)
Br. J. Pharmacol.
, vol.156
, pp. 454-465
-
-
Ito, B.R.1
Zhang, B.H.2
Cable, E.E.3
Song, X.4
Fujitaki, J.M.5
MacKenna, D.A.6
-
93
-
-
38649135692
-
The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans
-
Berkenstam A., Kristensen J., Mellström K., Carlsson B., Malm J., Rehnmark S., et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc. Natl. Acad. Sci. U S A. 2008, 105:663-667. 10.1073/pnas.0705286104.
-
(2008)
Proc. Natl. Acad. Sci. U S A.
, vol.105
, pp. 663-667
-
-
Berkenstam, A.1
Kristensen, J.2
Mellström, K.3
Carlsson, B.4
Malm, J.5
Rehnmark, S.6
-
94
-
-
77949349469
-
Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia
-
Ladenson P.W., Kristensen J.D., Ridgway E.C., Olsson A.G., Carlsson B., Klein I., et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N.Engl. J. Med. 2010, 362:906-916. 10.1097/OGX.0b013e3181f07bed.
-
(2010)
N.Engl. J. Med.
, vol.362
, pp. 906-916
-
-
Ladenson, P.W.1
Kristensen, J.D.2
Ridgway, E.C.3
Olsson, A.G.4
Carlsson, B.5
Klein, I.6
-
95
-
-
84888298822
-
Recent failures in antiatherosclerotic drug development: examples from the thyroxin receptor agonist, the secretory phospholipase A2 antagonist, and the acyl coenzyme A: cholesterol acyltransferase inhibitor programs
-
Stoekenbroek R.M., Kastelein J.J., Hovingh G.K. Recent failures in antiatherosclerotic drug development: examples from the thyroxin receptor agonist, the secretory phospholipase A2 antagonist, and the acyl coenzyme A: cholesterol acyltransferase inhibitor programs. Curr. Opin. Lipidol. 2013, 10.1097/MOL.0000000000000024.
-
(2013)
Curr. Opin. Lipidol.
-
-
Stoekenbroek, R.M.1
Kastelein, J.J.2
Hovingh, G.K.3
-
96
-
-
84884517120
-
Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist
-
Taub R., Chiang E., Chabot-Blanchet M., Kelly M.J., Reeves R.A., Guertin M.C., et al. Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist. Atherosclerosis 2013, 230:373-380. 10.1016/j.atherosclerosis.2013.07.056.
-
(2013)
Atherosclerosis
, vol.230
, pp. 373-380
-
-
Taub, R.1
Chiang, E.2
Chabot-Blanchet, M.3
Kelly, M.J.4
Reeves, R.A.5
Guertin, M.C.6
|